OKYO Pharma (NASDAQ:OKYO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 455.56% from the company’s current price. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.
OKYO Pharma Trading Up 14.5 %
Shares of NASDAQ:OKYO opened at $1.26 on Thursday. OKYO Pharma has a 52-week low of $0.81 and a 52-week high of $2.12. The firm has a fifty day moving average of $1.05 and a 200 day moving average of $1.24.
OKYO Pharma Company Profile
See Also
- Five stocks we like better than OKYO Pharma
- Transportation Stocks Investing
- Texas Roadhouse Stock Steering for New Highs This Year
- With Risk Tolerance, One Size Does Not Fit All
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is an Earnings Surprise?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.